Dianthus Therapeutics, Inc. /DE/ Leases Disclosure
9. Leases
The Company leases space under operating leases for administrative offices in New York, New York, and Waltham, Massachusetts. The Company previously leased wet laboratory space in Watertown, Massachusetts, but this lease terminated in March 2025.
The following table provides a summary of the components of lease costs and rent:
|
|
Year Ended |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
Operating lease cost |
|
$ |
396 |
|
|
$ |
422 |
|
Variable lease cost |
|
|
44 |
|
|
|
32 |
|
Total operating lease costs |
|
$ |
440 |
|
|
$ |
454 |
|
Cash paid for amounts included in the measurement of operating lease liabilities was $0.3 million and $0.4 million for the years ended December 31, 2025 and 2024, respectively.
The Company recorded operating lease costs of $0.4 million within the general and administrative expenses line item in the consolidated statements of operations and comprehensive loss during each of the years ended December 31, 2025 and 2024. The Company recorded operating lease costs of $24 thousand and $58 thousand within the research and development expenses line item in the consolidated statements of operations and comprehensive loss during the years ended December 31, 2025 and 2024, respectively.
Maturities of operating lease liabilities as of December 31, 2025 are as follows:
2026 |
|
$ |
367 |
|
2027 |
|
|
323 |
|
2028 |
|
|
318 |
|
2029 |
|
|
321 |
|
2030 |
|
|
324 |
|
Thereafter |
|
|
54 |
|
Total undiscounted operating lease payments |
|
|
1,707 |
|
Less: imputed interest |
|
|
(321 |
) |
Present value of operating lease liabilities |
|
$ |
1,386 |
|
|
|
|
|
|
Balance sheet classification: |
|
|
|
|
Current portion of operating lease liabilities |
|
$ |
367 |
|
Long-term operating lease liabilities |
|
|
1,019 |
|
Total operating lease liabilities |
|
$ |
1,386 |
|
The weighted-average remaining term of operating leases was 58 months and the weighted-average discount rate used to measure the present value of operating lease liabilities was 8.40% as of December 31, 2025.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 9, 2026 | Showing above |
| 2024 | Mar 11, 2025 | |
| 2023 | Mar 21, 2024 | |
| 2022 | Mar 23, 2023 | |
About Leases Disclosures
Lease disclosures under ASC 842 provide a comprehensive view of a company's leased asset portfolio, including the split between operating and finance leases, discount rates used to present-value future payments, and the maturity schedule of lease obligations. This section reveals a significant source of off-balance-sheet commitments that were largely hidden before the current standard.
Key signals: the weighted-average discount rate affects the size of recorded lease liabilities — a higher rate reduces the reported obligation, so compare the chosen rate against the company's incremental borrowing rate. The operating versus finance lease mix affects both EBITDA and operating income presentation. Watch the maturity table for concentration risk: large payment cliffs in specific years may create cash flow pressure. Variable lease payments excluded from the liability measurement represent real obligations that do not appear on the balance sheet. Compare total lease costs against prior-year operating lease expense to assess the true economic burden.